MiMedx Group reported third-quarter 2026 net sales of $62 million, a 45% decline from the prior-year period, driven by a 71% drop in Wound segment revenue due to Medicare reimbursement changes. Surgical franchise sales grew 9% year-over-year, representing nearly two-thirds of total net sales. The company returned to positive Adjusted EBITDA of $2 million and posted a GAAP net loss of $9 million. MiMedx also announced a favorable federal court ruling vacating the FDA's classification of AXIOFILL as a biological product and entered into a patent license agreement receiving $5 million annually for five years. The company raised its full-year 2026 net sales outlook to $250–$260 million and repaid its remaining term loan, ending with no debt outstanding. MiMedx operates in the healthcare sector, providing placental-derived healing solutions for wound care and surgical applications.
